U.S. Markets open in 9 hrs 13 mins

Wired News – Cellular Biomedicine's 48-Week Data off China-based Phase-I Clinical Trial Shows Positive Result for AlloJoin(TM) for Treatment of KOA

Stock Monitor: AnaptysBio Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CBMG as the Company's latest news hit the wire. On March 16, 2018, the Company shared the 48-week data from its China-based Phase-I clinical trial for AlloJoin™. AlloJoin™ is an off-the-shelf human adipose-derived mesenchymal progenitor cell therapy and is being tested for treatment of with knee osteoarthritis (KOA). Dr. ChengXiang (Chase) Dai, General Manager - Stem Cell Business Unit of CBMG presented the clinical trial data at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) conference in Hangzhou, China on March 16, 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for AnaptysBio, Inc. (NASDAQ: ANAB), which also belongs to the Healthcare sector as the Company Cellular Biomedicine Group. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ANAB

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Cellular Biomedicine Group most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CBMG

Commenting on the positive data from the 48-week period from clinical trial of AlloJoin™, Dr. ChengXiang Dai, said:

“The analysis of this early stage clinical study has indicated a good safety and potential efficacy for an off-the-shelf allogeneic haMPC therapy, which would allow us to continue to advance clinical trials to confirm efficacy of such cell therapy in preventing cartilage deterioration. The Company believes that the opportunity for patients to prevent further knee cartilage degeneration and improve the long-term quality of life using stem cells could be preferable to undergoing drug treatment with adverse side effects or painful and invasive knee replacement surgery.”

Results from 48-week data of Phase-I Clinical Trial of AlloJoin™

The Company's analysis of the 48-week data from Phase-I clinical trial for the 22 patients being treated using AlloJoin™ for KOA revealed the following:

  • The study met with the primary endpoint and showed that AlloJoin™ has good safety tolerance and showed early signs of efficacy in preventing cartilage deterioration. The total WOMAC scores (consisting of pain, stiffness, and function scores of joints) also showed that there was a marked improvement in patients after a 12-week period of being treated with AlloJoin™ and this improvement continued even at 48 weeks.
  • The secondary endpoint of the clinical trial was based on 48-week data from 3D spoiled gradient-recalled echo (SPGR) quantitative magnetic resonance imaging (MRI) for whole knee cartilage volume 3D spoiled gradient-recalled echo (SPGR) quantitative magnetic resonance imaging (MRI) for whole knee cartilage volume. The data showed an increased tendency against the zero tendency at the start of the clinical trial compared to normal deterioration in cartilage due to aging.
  • During the clinical trials, some side effects were observed in patients which were temporary local reactions like soreness and swelling at the injection site and other negligible systemic reactions. One patient complained of transient dizziness after being injected with AlloJoin™ and two patients dropped out of the clinical trials after complaining that the AlloJoin™ injections increased the pain in knee joints. However, no serious adverse effects were recorded during the AlloJoin™ clinical trial till date.

Details of AlloJoin™ Clinical trial

The AlloJoin™ clinical trial is a randomized, double-blind trial with three different cell dose groups from the 22 patients with knee osteoarthritis. Phase-I of the clinical trial is being conducted at the Shanghai Renji Hospital in China with Chunde Bao, MD, Professor of Medicine, Vice Chairman of the Chinese Rheumatology Association as the Principal Investigator. Phase-I clinical trials started in January 2016.

The primary endpoint of the clinical trial was to evaluate the safety of AlloJoin™ and the impact on knee-related pain, stiffness, and function. The secondary endpoint was to ascertain if there was evidence of cartilage repair at the end of 12 months which could be done by evaluating the changes of the knee joint cartilage's volume.

During the AlloJoin™ clinical trial out of the 22 patients that were enrolled, 20 patients were given two doses of AlloJoin™ injections at 3-week intervals. The follow-up on the 20 patients was done at 4, 8, 12, 24, 36, and 48 weeks to evaluate the safety and efficacy of the therapy. The assessment of the whole joint cartilage volume was conducted on 19 of the 22 patients using third-party quantitative MRI at the start of the clinical trial and at the end of 48 weeks.

About Cellular Biomedicine Group, Inc.

CBMG is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases. The Company's primary research and manufacturing facilities are in China and is GMP facilities in China include twelve independent cell production lines designed and managed as per Chinese and US GMP standards. CBMG's technology includes 2 major cell platforms:

  • Immune Cell therapy for treatment of a broad range of cancers using Cancer Vaccines, Chimeric Antigen Receptor T cell (CAR-T), and anti-PD-1 Technologies;
  • Human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases.

Stock Performance Snapshot

March 19, 2018 - At Monday's closing bell, Cellular Biomedicine's stock dropped 2.26%, ending the trading session at $19.45.

Volume traded for the day: 38.54 thousand shares.

Stock performance in the last month – up 8.66%; previous three-month period – up 85.24%; past twelve-month period – up 73.66%; and year-to-date - up 72.89%

After yesterday's close, Cellular Biomedicine's market cap was at $261.60 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors